title: Prognosis of small cell lung cancer patients with diabetes treated with metformin.
abstract: BACKGROUND
  It has been reported that metformin has an anticancer impact in various solid tumors, but its role in small cell lung cancer (SCLC) remains unclear. This study aimed to investigate the effect of metformin on survival in diabetic SCLC patients.
  
  
  METHODS
  A total of 79 SCLC patients with diabetes treated in our hospital between 2000 and 2010 were enrolled. The clinicopathological data and survival time were collected and evaluated. Univariate and multivariate analyses were used to investigate the association between metformin use and the survival of SCLC.
  
  
  RESULTS
  Among the 79 diabetic patients, 36 patients took metformin. The median OS and DFS were significantly better in the metformin group compared to non-metformin group (OS 18.0 vs 11.5 months, p < 0.001; DFS 10.8 vs 6.5 months, p < 0.001). Multivariate Cox analysis indicated that metformin use was an independent prognostic factor for long-term outcome (HR = 0.549, 95 % CI 0.198-0.978, p = 0.001).
  
  
  CONCLUSIONS
  The prognosis of SCLC patients with diabetes treated with metformin was improved, which might be considered a potential useful anticancer drug in treating SCLC patients.
authors.affiliation: Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Sanwei Road, Nankai District, Tianjin, 300100, China. xtbyln@163.com.
authors.forename: T
authors.initials: T
authors.lastname: Xu
authors.affiliation: Department of International Medical Center, Tianjin First Center Hospital, Fukang Road, Tianjin, 300192, China.
authors.forename: G
authors.initials: G
authors.lastname: Liang
authors.affiliation: Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Sanwei Road, Nankai District, Tianjin, 300100, China.
authors.forename: L
authors.initials: L
authors.lastname: Yang
authors.affiliation: Department of Respiratory Medicine, Tianjin Hospital of ITCWM, Nankai Hospital, Sanwei Road, Nankai District, Tianjin, 300100, China.
authors.forename: F
authors.initials: F
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016022:Case-Control Studies; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy*; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000077146:Irinotecan; D008175:Lung Neoplasms / Q000150:complications / Q000628:therapy*; D008297:Male; D008687:Metformin / Q000627:therapeutic use*; D008875:Middle Aged; D015999:Multivariate Analysis; D017671:Platinum Compounds / Q000008:administration & dosage; D011013:Pneumonectomy; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000150:complications / Q000628:therapy*
chemical_list: D007004:Hypoglycemic Agents; D017671:Platinum Compounds; D005047:Etoposide; D000077146:Irinotecan; D008687:Metformin; D002166:Camptothecin
keywords: Diabetes; Metformin; Prognosis; Small cell lung cancer